$ADMA
ADMA Biologics Inc

2023 Q1 Form 10-K Financial Statement

#000114036123013467 Filed on March 23, 2023

View on sec.gov

Income Statement

Concept 2023 Q1 2022 Q4 2022
Revenue $56.91M $49.98M $154.1M
YoY Change 95.56% 89.45% 90.36%
Cost Of Revenue $40.40M $35.80M $118.8M
YoY Change 58.8% 56.55% 48.95%
Gross Profit $16.51M $14.18M $35.27M
YoY Change 350.92% 303.73% 2905.68%
Gross Profit Margin 29.01% 28.36% 22.89%
Selling, General & Admin $14.51M $18.98M $52.46M
YoY Change 5.93% 20.18% 22.29%
% of Gross Profit 87.88% 133.9% 148.75%
Research & Development $855.4K $1.074M $3.614M
YoY Change 37.05% 47.37% -0.89%
% of Gross Profit 5.18% 7.58% 10.25%
Depreciation & Amortization $1.900M $1.937M $6.400M
YoY Change 35.71% 27.62% 33.33%
% of Gross Profit 11.51% 13.66% 18.15%
Operating Expenses $17.33M $20.24M $74.63M
YoY Change -6.23% 21.15% 25.33%
Operating Profit -$813.3K -$6.059M -$39.37M
YoY Change -94.51% -54.07% -32.56%
Interest Expense $6.115M -$5.735M $19.28M
YoY Change 80.45% 73.07% 47.66%
% of Operating Profit
Other Income/Expense, Net -$5.975M -$438.5K -$26.54M
YoY Change -41.38% 202.8% 99.93%
Pretax Income -$6.789M -$12.23M -$65.90M
YoY Change -72.85% -26.53% -8.02%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$6.789M -$12.23M -$65.90M
YoY Change -72.85% -26.53% -8.02%
Net Earnings / Revenue -11.93% -24.47% -42.77%
Basic Earnings Per Share -$0.03 -$0.33
Diluted Earnings Per Share -$0.03 -$0.06 -$0.33
COMMON SHARES
Basic Shares Outstanding 222.2M 196.8M 197.9M
Diluted Shares Outstanding 221.9M 197.9M

Balance Sheet

Concept 2023 Q1 2022 Q4 2022
SHORT-TERM ASSETS
Cash & Short-Term Investments $69.20M $86.52M $86.52M
YoY Change -0.43% 69.35% 69.35%
Cash & Equivalents $69.20M $86.52M $86.52M
Short-Term Investments
Other Short-Term Assets $4.379M $5.095M $5.095M
YoY Change -20.67% 17.42% 17.42%
Inventory $164.0M $163.3M $163.3M
Prepaid Expenses
Receivables $26.52M $15.51M $15.51M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $264.1M $270.4M $270.4M
YoY Change 10.13% 29.55% 29.55%
LONG-TERM ASSETS
Property, Plant & Equipment $57.37M $58.26M $68.75M
YoY Change 7.8% 14.38% 18.13%
Goodwill $3.530M $3.500M
YoY Change -0.84%
Intangibles $834.6K $1.013M
YoY Change -41.38%
Long-Term Investments
YoY Change
Other Assets $4.719M $4.770M $4.770M
YoY Change 66.99% 17.28% 17.28%
Total Long-Term Assets $76.70M $78.06M $78.06M
YoY Change 12.41% 15.6% 15.6%
TOTAL ASSETS
Total Short-Term Assets $264.1M $270.4M $270.4M
Total Long-Term Assets $76.70M $78.06M $78.06M
Total Assets $340.8M $348.5M $348.5M
YoY Change 10.63% 26.14% 26.14%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $12.96M $13.23M $13.23M
YoY Change -8.21% 6.44% 6.44%
Accrued Expenses $21.59M $24.10M $24.10M
YoY Change 51.81% 43.5% 43.5%
Deferred Revenue $142.8K $142.8K
YoY Change 0.0%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $36.73M $39.27M $39.27M
YoY Change 16.35% 29.26% 29.26%
LONG-TERM LIABILITIES
Long-Term Debt $144.3M $142.8M $142.8M
YoY Change 4.25% 50.56% 50.56%
Other Long-Term Liabilities $338.7K $350.5K $14.39M
YoY Change -96.95% -11.8% 46.28%
Total Long-Term Liabilities $338.7K $350.5K $157.2M
YoY Change -99.77% -11.8% 50.16%
TOTAL LIABILITIES
Total Short-Term Liabilities $36.73M $39.27M $39.27M
Total Long-Term Liabilities $338.7K $350.5K $157.2M
Total Liabilities $195.1M $196.5M $196.5M
YoY Change 7.75% 45.46% 45.46%
SHAREHOLDERS EQUITY
Retained Earnings -$484.8M -$478.0M
YoY Change 15.99%
Common Stock $22.23K $22.18K
YoY Change 13.28%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $145.7M $152.0M $152.0M
YoY Change
Total Liabilities & Shareholders Equity $340.8M $348.5M $348.5M
YoY Change 10.63% 26.14% 26.14%

Cashflow Statement

Concept 2023 Q1 2022 Q4 2022
OPERATING ACTIVITIES
Net Income -$6.789M -$12.23M -$65.90M
YoY Change -72.85% -26.53% -8.02%
Depreciation, Depletion And Amortization $1.900M $1.937M $6.400M
YoY Change 35.71% 27.62% 33.33%
Cash From Operating Activities -$14.72M -$7.379M -$59.51M
YoY Change -43.41% -77.95% -47.04%
INVESTING ACTIVITIES
Capital Expenditures $1.945M $3.749M $13.91M
YoY Change -31.58% -201.98% 2.96%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$1.945M -$3.749M -$13.91M
YoY Change -31.58% 1.98% 2.96%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $64.65M
YoY Change -46.64%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -650.5K 62.74M 108.9M
YoY Change -101.38% 16.58% -10.08%
NET CHANGE
Cash From Operating Activities -14.72M -7.379M -59.51M
Cash From Investing Activities -1.945M -3.749M -13.91M
Cash From Financing Activities -650.5K 62.74M 108.9M
Net Change In Cash -17.32M 51.62M 35.43M
YoY Change -194.04% 209.47% -833.28%
FREE CASH FLOW
Cash From Operating Activities -$14.72M -$7.379M -$59.51M
Capital Expenditures $1.945M $3.749M $13.91M
Free Cash Flow -$16.67M -$11.13M -$73.42M
YoY Change -42.24% -62.64% -41.68%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
39266942
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
30378315
CY2022Q4 us-gaap Senior Long Term Notes
SeniorLongTermNotes
142833063
CY2021Q4 us-gaap Senior Long Term Notes
SeniorLongTermNotes
94866239
CY2022Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
1833031
CY2021Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
1975865
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
10704176
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
7462388
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
350454
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
397351
CY2022Q4 us-gaap Liabilities
Liabilities
196487666
CY2021Q4 us-gaap Liabilities
Liabilities
135080158
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
221816930
CY2021 us-gaap Cost Of Revenue
CostOfRevenue
79769341
CY2022 us-gaap Gross Profit
GrossProfit
35265157
CY2021 us-gaap Gross Profit
GrossProfit
1173284
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3613764
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3646060
CY2022 us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
17843096
CY2021 us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
12288723
CY2022 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
715353
CY2021 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
715353
CY2022 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
52458024
CY2022 us-gaap Operating Expenses
OperatingExpenses
74630237
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-39365080
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-58373741
CY2021 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-251575
CY2022 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-26538870
CY2021 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-13273877
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-71647618
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
141172566
CY2022 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
64645289
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-65903950
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
151974215
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-65903950
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-71647618
CY2022 us-gaap Depreciation And Amortization
DepreciationAndAmortization
7113369
CY2021 us-gaap Depreciation And Amortization
DepreciationAndAmortization
5495502
CY2022 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-426536
CY2021 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-220761
CY2021 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
0
CY2022 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
64645289
CY2021 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
121144103
CY2021 adma Payment Of Debt Refinancing Fees
PaymentOfDebtRefinancingFees
0
CY2022 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
151750000
CY2021 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
0
CY2022 adma Taxes Paid On Vested Restricted Stock Units
TaxesPaidOnVestedRestrictedStockUnits
2898840
CY2021 adma Taxes Paid On Vested Restricted Stock Units
TaxesPaidOnVestedRestrictedStockUnits
61598
CY2022 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
36684
CY2021 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
34299
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
108851852
CY2022 dei Amendment Flag
AmendmentFlag
false
CY2022 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2022 dei Entity Central Index Key
EntityCentralIndexKey
0001368514
CY2022 dei Auditor Firm
AuditorFirmId
596
CY2022 dei Document Type
DocumentType
10-K
CY2022 dei Document Annual Report
DocumentAnnualReport
true
CY2022 dei Document Period End Date
DocumentPeriodEndDate
2022-12-31
CY2022 dei Document Transition Report
DocumentTransitionReport
false
CY2022 dei Entity File Number
EntityFileNumber
001-36728
CY2022 dei Entity Registrant Name
EntityRegistrantName
ADMA BIOLOGICS, INC.
CY2022 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
56-2590442
CY2022 dei Entity Address Address Line1
EntityAddressAddressLine1
465 State Route 17
CY2022 dei Entity Address City Or Town
EntityAddressCityOrTown
Ramsey
CY2022 dei Entity Address State Or Province
EntityAddressStateOrProvince
NJ
CY2022 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
07446
CY2022 dei City Area Code
CityAreaCode
201
CY2022 dei Local Phone Number
LocalPhoneNumber
478-5552
CY2022 dei Security12b Title
Security12bTitle
Common stock, par value $0.0001 per share
CY2022 dei Trading Symbol
TradingSymbol
ADMA
CY2022 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2022 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2022 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022 dei Entity Small Business
EntitySmallBusiness
true
CY2022 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2022 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2022 dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 dei Entity Public Float
EntityPublicFloat
372622681
CY2023Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
222155625
CY2022 dei Auditor Name
AuditorName
CohnReznick LLP
CY2022 dei Auditor Location
AuditorLocation
Parsippany, New Jersey
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
86521542
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
51089118
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
15505048
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
28576857
CY2022Q4 us-gaap Inventory Net
InventoryNet
163280047
CY2021Q4 us-gaap Inventory Net
InventoryNet
124724091
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5095146
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4339245
CY2022Q4 us-gaap Assets Current
AssetsCurrent
270401783
CY2021Q4 us-gaap Assets Current
AssetsCurrent
208729311
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
58261481
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
50935074
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1013415
CY2021Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1728768
CY2022Q4 us-gaap Goodwill
Goodwill
3529509
CY2021Q4 us-gaap Goodwill
Goodwill
3529509
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
10485447
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
7262658
CY2022Q4 adma Deposits And Other Noncurrent Assets
DepositsAndOtherNoncurrentAssets
4770246
CY2021Q4 adma Deposits And Other Noncurrent Assets
DepositsAndOtherNoncurrentAssets
4067404
CY2022Q4 us-gaap Assets
Assets
348461881
CY2021Q4 us-gaap Assets
Assets
276252724
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
13229390
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
12429409
CY2022Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
24989349
CY2021Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
17214988
CY2022Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
142834
CY2021Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
142834
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
905369
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
591084
CY2022Q4 adma Long Term Liability End Of Term Fee Payable
LongTermLiabilityEndOfTermFeePayable
1500000
CY2021Q4 adma Long Term Liability End Of Term Fee Payable
LongTermLiabilityEndOfTermFeePayable
0
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
221816930
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
195813817
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
195813817
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
22182
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
19581
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
629968704
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
553265706
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-478016671
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-412112721
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
151974215
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
141172566
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
348461881
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
276252724
CY2022 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
154079692
CY2021 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
80942625
CY2022 us-gaap Cost Of Revenue
CostOfRevenue
118814535
CY2021 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
42896889
CY2021 us-gaap Operating Expenses
OperatingExpenses
59547025
CY2022 us-gaap Investment Income Interest
InvestmentIncomeInterest
44833
CY2021 us-gaap Investment Income Interest
InvestmentIncomeInterest
34532
CY2022 us-gaap Interest Expense
InterestExpense
19279373
CY2021 us-gaap Interest Expense
InterestExpense
13056834
CY2022 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-6669941
CY2021 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
CY2022 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-634389
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-65903950
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-71647618
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.33
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.33
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.51
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.51
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
197874895
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
197874895
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
139578538
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
139578538
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
88249426
CY2021 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
3488253
CY2021 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
121144103
CY2021 adma Vesting Of Restricted Stock Units Net Of Shares Withheld For Taxes And Retired Amount
VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredAmount
-61598
CY2022 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
5214531
CY2022 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
9569604
CY2022 adma Vesting Of Restricted Stock Units Net Of Shares Withheld For Taxes And Retired Amount
VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredAmount
-2898840
CY2022 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
175015
CY2022 us-gaap Paid In Kind Interest
PaidInKindInterest
2997746
CY2021 us-gaap Paid In Kind Interest
PaidInKindInterest
0
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
5214531
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
3488253
CY2022 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
2401669
CY2021 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
1897373
CY2022 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-6669941
CY2021 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
CY2022 adma Amortization Of License Revenue
AmortizationOfLicenseRevenue
-142834
CY2021 adma Amortization Of License Revenue
AmortizationOfLicenseRevenue
-142834
CY2022 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-13071809
CY2021 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
15339567
CY2022 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
38555957
CY2021 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
43188489
CY2022 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
755900
CY2021 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1292779
CY2022 adma Increase Decrease In Deposits And Other Assets
IncreaseDecreaseInDepositsAndOtherAssets
-122468
CY2021 adma Increase Decrease In Deposits And Other Assets
IncreaseDecreaseInDepositsAndOtherAssets
1775205
CY2022 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
799981
CY2021 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1355700
CY2022 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
7534572
CY2021 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
8341341
CY2022 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-502238
CY2021 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
218580
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-59508257
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-112368982
CY2022 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
13911171
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
13511258
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-13911171
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-13511258
CY2022 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
100000000
CY2022 adma Payment Of Debt Refinancing Fees
PaymentOfDebtRefinancingFees
2000000
CY2022 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
175015
CY2021 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0
CY2022 us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
2782928
CY2021 us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
0
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
121048206
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
35432424
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-4832034
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
51089118
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
55921152
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
86521542
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
51089118
CY2022 adma Number Of Plasma Collection Facilities Under Development
NumberOfPlasmaCollectionFacilitiesUnderDevelopment
10
CY2022 adma Number Of Current Fda Licensed Plasma Collection Facilities
NumberOfCurrentFDALicensedPlasmaCollectionFacilities
8
CY2022 adma Number Of Fda Approved Product
NumberOfFDAApprovedProduct
3
CY2022Q4 adma Working Capital
WorkingCapital
231100000
CY2022Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
86500000
CY2022Q1 us-gaap Proceeds From Issuance Of Senior Long Term Debt
ProceedsFromIssuanceOfSeniorLongTermDebt
47000000
CY2022Q4 adma Accounts Receivable Allowance For Contractual Credits And Doubtful Accounts
AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts
100000
CY2021Q4 adma Accounts Receivable Allowance For Contractual Credits And Doubtful Accounts
AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts
200000
CY2021Q4 us-gaap Goodwill
Goodwill
3500000
CY2022Q4 us-gaap Goodwill
Goodwill
3500000
CY2021 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2022 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2022 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2021 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2022 us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
2200000
CY2021 us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
1400000
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P4Y
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Requisite Service Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
P10Y
CY2022 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
24648346
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
16876015
CY2022Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
48644527
CY2021Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
36755720
CY2022Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
56170853
CY2021Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
58968535
CY2022Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
58464667
CY2021Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
28999836
CY2022Q4 us-gaap Inventory Net
InventoryNet
163280047
CY2021Q4 us-gaap Inventory Net
InventoryNet
124724091
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
77738022
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
64206927
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
19476541
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
13271853
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
58261481
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
50935074
CY2022 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
6400000
CY2021 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
4800000
CY2022Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
5007467
CY2022Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
3994052
CY2022Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
1013415
CY2021Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
5007467
CY2021Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
3278699
CY2021Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
1728768
CY2022 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
700000
CY2021 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
700000
CY2022Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Next Rolling Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths
715352
CY2022Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Rolling Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo
298063
CY2021Q4 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
53800000
CY2022Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
1.99
CY2020Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
2.82
CY2022Q4 adma Accrued Rebates Current
AccruedRebatesCurrent
11436484
CY2021Q4 adma Accrued Rebates Current
AccruedRebatesCurrent
5040200
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
3166896
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
4739651
CY2022Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
4193919
CY2021Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
4066109
CY2022Q4 adma Accrued Testing Current
AccruedTestingCurrent
309867
CY2021Q4 adma Accrued Testing Current
AccruedTestingCurrent
1189970
CY2022Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
4086379
CY2021Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
1197337
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1795804
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
981721
CY2022Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
24989349
CY2021Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
17214988
CY2022Q4 adma Senior Notes Payable Before Debt Discount
SeniorNotesPayableBeforeDebtDiscount
154747746
CY2021Q4 adma Senior Notes Payable Before Debt Discount
SeniorNotesPayableBeforeDebtDiscount
100000000
CY2022Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
11914683
CY2021Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
5133761
CY2022Q4 us-gaap Senior Long Term Notes
SeniorLongTermNotes
142833063
CY2021Q4 us-gaap Senior Long Term Notes
SeniorLongTermNotes
94866239
CY2022Q1 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
13900000
CY2022Q4 us-gaap Preferred Stock Capital Shares Reserved For Future Issuance
PreferredStockCapitalSharesReservedForFutureIssuance
10000000
CY2021Q4 us-gaap Preferred Stock Capital Shares Reserved For Future Issuance
PreferredStockCapitalSharesReservedForFutureIssuance
10000000
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
221816930
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
195813817
CY2022Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
29177763
CY2021Q4 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
57500000
CY2021Q4 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
57500000
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1194032
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1895550
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P6Y1M6D
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y1M6D
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y3M18D
CY2022Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
8256211
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y1M6D
CY2022Q4 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
3.37
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
7640242
CY2022Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
6213959
CY2022 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
P5Y3M18D
CY2022Q4 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
3.8
CY2022Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
3886055
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
5214531
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
3488253
CY2022 adma Number Of Fda Licensed Plasma Collection Facilities Approved
NumberOfFDALicensedPlasmaCollectionFacilitiesApproved
4
CY2021 adma Number Of Fda Inspections
NumberOfFDAInspections
2
CY2022 adma Plasma Supply Agreement Term
PlasmaSupplyAgreementTerm
P10Y
CY2012Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2000000
CY2019Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1500000
CY2022 adma Number Of Tranches
NumberOfTranches
2
CY2022 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-13839830
CY2021 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-15045999
CY2022 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-1773349
CY2021 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-251839
CY2022 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
15117100
CY2021 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
14618762
CY2022 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
211343
CY2021 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
239585
CY2022 adma Effective Income Tax Rate Reconciliation Change In Federal Net Operating Loss Amount
EffectiveIncomeTaxRateReconciliationChangeInFederalNetOperatingLossAmount
0
CY2021 adma Effective Income Tax Rate Reconciliation Change In Federal Net Operating Loss Amount
EffectiveIncomeTaxRateReconciliationChangeInFederalNetOperatingLossAmount
623679
CY2022 adma Effective Income Tax Rate Reconciliation Section162 M Disallowance
EffectiveIncomeTaxRateReconciliationSection162MDisallowance
862027
CY2021 adma Effective Income Tax Rate Reconciliation Section162 M Disallowance
EffectiveIncomeTaxRateReconciliationSection162MDisallowance
63515
CY2022 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
-154605
CY2021 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
231467
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
81526316
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
73036983
CY2022Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
407280
CY2021Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
31333
CY2022Q4 us-gaap Deferred Tax Asset Interest Carryforward
DeferredTaxAssetInterestCarryforward
12194369
CY2021Q4 us-gaap Deferred Tax Asset Interest Carryforward
DeferredTaxAssetInterestCarryforward
6013040
CY2022Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
881782
CY2021Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
977046
CY2022Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
479510
CY2021Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
519819
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
1236128
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
1030064
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
96725385
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
81608285
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
96725385
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
81608285
CY2022Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2021Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2021 us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
-3900000
CY2021 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
-3900000
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2022 adma Operating Lease Incremental Borrowing Rate Percent
OperatingLeaseIncrementalBorrowingRatePercent
0.13
CY2021 adma Operating Lease Incremental Borrowing Rate Percent
OperatingLeaseIncrementalBorrowingRatePercent
0.14
CY2022 us-gaap Operating Lease Expense
OperatingLeaseExpense
2100000
CY2021 us-gaap Operating Lease Expense
OperatingLeaseExpense
1400000
CY2022 us-gaap Operating Lease Payments
OperatingLeasePayments
1800000
CY2021 us-gaap Operating Lease Payments
OperatingLeasePayments
1400000
CY2022Q4 adma Lessee Operating Lease Right Of Use Asset Related To Property Lease
LesseeOperatingLeaseRightOfUseAssetRelatedToPropertyLease
4000000
CY2022Q4 adma Lessee Operating Lease Liabilities Related To Property Lease
LesseeOperatingLeaseLiabilitiesRelatedToPropertyLease
4000000
CY2022 adma Number Of New Property Leases
NumberOfNewPropertyLeases
2
CY2021Q4 adma Lessee Operating Lease Right Of Use Asset Related To Property Lease
LesseeOperatingLeaseRightOfUseAssetRelatedToPropertyLease
3600000
CY2021Q4 adma Lessee Operating Lease Liabilities Related To Property Lease
LesseeOperatingLeaseLiabilitiesRelatedToPropertyLease
3600000
CY2021 adma Number Of New Property Leases
NumberOfNewPropertyLeases
4
CY2022Q4 adma Operating And Financing Lease Liability
OperatingAndFinancingLeaseLiability
11600000
CY2021Q4 adma Operating And Financing Lease Liability
OperatingAndFinancingLeaseLiability
8100000
CY2022Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P8Y4M24D
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
2367057
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
2343314
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
2366432
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
2116036
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
2040690
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
8238571
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
19472100
CY2022Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
7862555
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
905369
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
10704176
CY2022 adma Operating Leases Rent Expense
OperatingLeasesRentExpense
10000
CY2022Q4 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P5Y
CY2022 adma Number Of Plasma Collection Facilities Under Development
NumberOfPlasmaCollectionFacilitiesUnderDevelopment
10
CY2022 adma Number Of Operational Collection Plasma Facilities
NumberOfOperationalCollectionPlasmaFacilities
9
CY2022 adma Number Of Fda Licensed Plasma Collection Facilities
NumberOfFDALicensedPlasmaCollectionFacilities
7
CY2022 adma Number Of Fda Licensed Plasma Collection Facilities Received Approval
NumberOfFDALicensedPlasmaCollectionFacilitiesReceivedApproval
3
CY2022 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
154079692
CY2022 us-gaap Cost Of Revenue
CostOfRevenue
118814535
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-39365080
CY2022 adma Interest And Other Nonoperating Income Expense
InterestAndOtherNonoperatingIncomeExpense
-19868929
CY2022 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-6669941
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-65903950
CY2022 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
13911171
CY2022 us-gaap Depreciation And Amortization
DepreciationAndAmortization
7113369
CY2022Q4 us-gaap Assets
Assets
348461881
CY2021 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
80942625
CY2021 us-gaap Cost Of Revenue
CostOfRevenue
79769341
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-58373741
CY2021 adma Interest And Other Nonoperating Income Expense
InterestAndOtherNonoperatingIncomeExpense
-13273877
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-71647618
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
13511258
CY2021 us-gaap Depreciation And Amortization
DepreciationAndAmortization
5495502
CY2021Q4 us-gaap Assets
Assets
276252724
CY2022 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
1300000
CY2021 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
1100000
CY2022 us-gaap Interest Paid Net
InterestPaidNet
13879958
CY2021 us-gaap Interest Paid Net
InterestPaidNet
11159461
CY2022 adma Equipment Acquired Reflected In Accounts Payable And Accrued Liabilities
EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities
1494916
CY2021 adma Equipment Acquired Reflected In Accounts Payable And Accrued Liabilities
EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities
1352627
CY2022 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
4048099
CY2021 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
3554473
CY2022 adma Warrants Issued In Connection With Notes Payable
WarrantsIssuedInConnectionWithNotesPayable
9569604
CY2021 adma Warrants Issued In Connection With Notes Payable
WarrantsIssuedInConnectionWithNotesPayable
0
CY2022 adma Plasma Purchased
PlasmaPurchased
47700000
CY2021 adma Plasma Purchased
PlasmaPurchased
42000000
CY2022 adma Percentage Of Inventory Purchases
PercentageOfInventoryPurchases
0.65
CY2021 adma Percentage Of Inventory Purchases
PercentageOfInventoryPurchases
0.69
CY2022 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
154079692
CY2021 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
80942625

Files In Submission

Name View Source Status
adma-20221231_pre.xml Edgar Link unprocessable
adma-20221231_def.xml Edgar Link unprocessable
adma-20221231_cal.xml Edgar Link unprocessable
0001140361-23-013467-index-headers.html Edgar Link pending
0001140361-23-013467-index.html Edgar Link pending
0001140361-23-013467.txt Edgar Link pending
0001140361-23-013467-xbrl.zip Edgar Link pending
adma-20221231.xsd Edgar Link pending
brhc10049985_10k.htm Edgar Link pending
brhc10049985_ex10-251.htm Edgar Link pending
brhc10049985_ex21-1.htm Edgar Link pending
brhc10049985_ex23-1.htm Edgar Link pending
brhc10049985_ex31-1.htm Edgar Link pending
brhc10049985_ex31-2.htm Edgar Link pending
brhc10049985_ex32-1.htm Edgar Link pending
brhc10049985_ex32-2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
adma-20221231_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
brhc10049985_10k_htm.xml Edgar Link completed
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending